Stock Market NewsRanked by Importance
Most financial news doesn't move stocks. Earnings beats, FDA decisions, and merger announcements are what you actually need to read. StockGlow puts them first, automatically.
Free plan available forever. See how it works
Live
News Feed
20+
Catalyst Types
$0
To Start
Sourced from
How it works
Before: scroll 200 headlines.
After: the important ones are already at the top.
Not a firehose of headlines. The stories worth your attention today, ranked before you open the app.
Financial news from across the web, in one ranked feed.
Benzinga, GlobeNewsWire, Motley Fool, Investing.com, and more publishers in a single ranked feed. You see each story once. Duplicates are automatically removed.
FDA approvals rank above analyst opinions. Every time.
Each story is scored on source credibility, catalyst type, market sentiment, and recency. The ranking is automatic. You never have to think about it.
Your stocks surface first. Everything else fills in.
Add your tickers and the feed filters down to just those stocks. On quiet days, the top market-wide stories fill in so you never see an empty feed.
Nvidia Reports Q4 Revenue of $22.1B, Beats Estimates by $1.4B as Data Center Demand Surges
Revenue and EPS both exceeded analyst consensus by a wide margin; data center segment up 409% YoY.
FDA Grants Full Approval to Moderna's Next-Generation mRNA Cancer Vaccine Following Phase 3 Data
Full approval removes regulatory uncertainty and opens reimbursement pathway; broader patient access expected.
Intel Announces 15,000 Job Cuts and $10B Cost Reduction Plan Amid Foundry Business Losses
Large-scale layoffs signal deeper competitive pressure; foundry losses worse than expected.
Morgan Stanley Raises Apple Price Target to $230, Cites iPhone 16 Upgrade Cycle Momentum
Upgrade cycle acceleration and AI integration seen as tailwinds for services revenue growth.
Features
The 3 stories that matter today. Not the 300 that don't.
For investors who follow 10–30 stocks and check in once or twice a day. Not full-time traders.
The biggest story ranks first
An FDA approval surfaces before a routine press release. An earnings beat before an analyst note. Always. Importance moves stocks, not clicks.
A verdict before you open it
Scroll the feed and you already know what the market thinks, before you open a single article. Each story is tagged positive, negative, or neutral with a one-line reason when available.
Your watchlist, delivered
Every morning, a digest of the most important news for your specific tickers, in your inbox before you open the app. No watchlist yet? You get the top market stories instead.
Every earnings date, weeks in advance
Splits, dividends, and earnings dates for your whole watchlist in one calendar view, weeks before they happen. Nothing about your stocks catches you off guard.
See the price reaction without switching apps
When a story breaks, pull up the chart right there. Daily and weekly candlestick charts with volume. No tab-switching, no losing your place in the feed.
Filter to only the news you care about
Earnings, FDA decisions, mergers, analyst upgrades, insider activity, and 15+ more, each tagged and filterable so biotech drama never buries the earnings beat you needed to see.
Works on any device. No setup required.
Start reading freeWho it's for
You don't have time to read 200 headlines a day. You don't need to.
The buy-and-hold investor
You own 10–20 stocks and check the market once or twice a day. You don't trade actively — but you need to know the moment something material changes.
Open the app, see the one thing that changed for your portfolio, close it. Done in under a minute.
The multi-stock investor
You follow more tickers than you have time to research. You need fast signal across many positions without spending an hour sorting through headlines.
Add all 20 tickers. The most important story for each one is already at the top when you open the feed.
The catalyst hunter
You hold biotech, small-cap, or high-conviction positions where FDA decisions and earnings beats can move the stock significantly overnight.
The FDA approval you've been watching surfaces immediately, flagged as a major catalyst before you'd have scrolled to it.
Pricing
Priced for investors, not institutions.
Most financial data platforms charge $100–$200/month. StockGlow Pro is $10.
Free
Forever. No tricks.
- 25 ranked articles per day
- Up to 3 watchlist tickers
- Sentiment tags where available
- Daily email digest
- 20+ catalyst categories
Pro
7-day free trial · cancel anytime
- Read every story about your stocks, no daily cap
- Follow up to 20 tickers, all filtered to your watchlist
- Every earnings date, dividend, and split on your calendar, weeks ahead
- Pull up a chart the moment a story breaks, without switching tabs
- Morning digest personalized to your specific tickers
- Filter by 20+ event types, filtered to only what you care about
Both plans include ranked news, sentiment tags, and your daily email digest.
FAQ
Questions people actually ask
I already use Yahoo Finance and CNBC. Why do I need this?
Yahoo Finance shows every headline in the order it was published. If you follow 15 stocks and check in once a day, you're scrolling past 80 irrelevant articles to find the 2 that actually matter. StockGlow does that sorting automatically. An FDA approval ranks above an analyst note, every time. The problem was never access to news. It was knowing which news to care about.
Is $10/month worth it compared to free tools?
At $10/month, that's about 33 cents a day to stop guessing which headlines matter and just read the right ones. Free tools show you everything and let you sort it out. StockGlow shows you what matters first. If you follow stocks with real money in them, the cost of missing an FDA decision or an earnings surprise is orders of magnitude higher than $10.
Will it cover the specific stocks I follow?
Yes. Add up to 3 tickers to your watchlist on the free plan (20 on Pro) and StockGlow filters the feed to just those stocks. If there isn't enough watchlist news on a given day, it falls back to the top market-wide stories so you're never looking at an empty feed.
How does the ranking actually work?
Every article is scored across four factors: source credibility (wire services and major publishers outrank opinion blogs), catalyst type (FDA decisions and earnings beats outrank analyst opinion pieces), sentiment signal, and recency. The scores are never shown to you. They just determine what floats to the top.
Is this for active traders or long-term investors?
Both — but it's especially useful if you're a buy-and-hold investor who follows 10–30 stocks and checks in once or twice a day. You don't need to catch every tick. You just need to know when something material changes for a stock you own.
What's the difference between free and Pro?
Free gives you 25 ranked articles per day, 3 watchlist tickers, and a daily email digest. Pro ($10/month) removes the article cap, raises your watchlist to 20 tickers, and adds candlestick charts and an events calendar with earnings dates, splits, and dividends. Pro includes a 7-day free trial.
The story that moves your stockis already out there.
Make sure you're reading it.
Join free. Add a ticker. See what's happening right now.
Start Reading FreeTakes 30 seconds to set up. Add a ticker. Your ranked feed is ready immediately.
Already have an account? Sign in